Altered Carbohydrate Antigen Expression In Colorectal Cancer And Polyps

  • Young S. Kim
Part of the Topics in Gastroenterology book series (TGEN)


Cancer of the colon and rectum is the most common gastrointestinal malignancy in many Western countries. In the United States, it is estimated that in 1989 there will be 150,000 new cases of colorectal cancer diagnosed and that 65,000 deaths from colorectal cancer will occur. The overall 5-year survival rate for patients with colorectal cancer is only 40–45%, a figure that has changed very little over the last two decades.1 Disease prevention appears to provide the best hope for improving the outcome of individuals with colorectal cancer. There are two approaches to disease prevention: Primary prevention involves identifying and eliminating the cause of the disease and also includes careful monitoring of populations at high risk for developing the disease. In the case of colorectal cancer, various environmental and host factors have been suggested to play a role in carcinogenesis, but the actual causative agents are not yet known. Recently, some progress has been made in identifying subjects at high risk for developing colorectal cancers among family members of familial polyposis coli or colon cancer family syndromes. The approach has been to investigate the biochemical or cell proliferative activities in normal appearing colonic mucosa (i.e., “flat mucosa”) in an effort to identify the genotype carrier state and to monitor the progression to severe dysplasia in affected patients.2–5


Sialic Acid Blood Group Distal Colon Adenomatous Polyp Hyperplastic Polyp 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bresalier RS, Boland CR, Sack TL, Kim YS. Cancer of the gastrointestinal tract. In: Gastroenterology Annual, Vol 3 (Kern F, Blum AL, eds.). New York: Elsevier, 1986, pp. 413–469.Google Scholar
  2. 2.
    Luk GD, Baylin SB. Ornithine decarboxylase as a biologic marker in familial colonic polyposis. N Engl J Med 1984;311:80–83.PubMedCrossRefGoogle Scholar
  3. 3.
    Lipkin M, Blattner WE, Fraumeni JF Jr, Lynch HT, Deschner E, Winawer S. Tritiated thymidine labeling distribution as a marker for hereditary predisposition to colon cancer. Cancer Res 1983;43:1899–1904.PubMedGoogle Scholar
  4. 4.
    Yonezawa S, Nakamura T, Tanaka S, Sato E. Binding of ulex europeus agglutinin-1 in polyposis coli: Comparative study with solitary adenoma in sigmoid colon and rectum. J Natl Cancer Inst 1983;71:19–23.PubMedGoogle Scholar
  5. 5.
    Boland CR, Lance P, Levin B, Riddell RH, Kim YS. Abnormal goblet cell glycoconjugates in rectal biopsies associated with an increased risk of neoplasia in patients with ulcerative colitis: Early results of a prospective study. Gut 1984;25:1364–1371.PubMedCrossRefGoogle Scholar
  6. 6.
    Gilbertson VA. Proctosigmoidoscopy and polypectomy in reducing the incidence to rectal cancer. Cancer 1974;34:936–939.CrossRefGoogle Scholar
  7. 7.
    Simon JB. Occult blood screening for colorectal carcinoma: A critical review. Gastroenterology 1985;88:820–837.PubMedGoogle Scholar
  8. 8.
    Neville AM. International union against cancer report: Workshop on immunodiagnosis. Cancer Res 1986;46:3744–3746.Google Scholar
  9. 9.
    Schlom J. Basic principles and applications of monoclonal antibodies in the management of carcinomas: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1986;46:3225–3238.PubMedGoogle Scholar
  10. 10.
    Hakomori S. Aberrant glycosylation in cancer cell membranes as focussed on glycolipids: overview and perspectives. Cancer Res 1985;45:2405–2414.PubMedGoogle Scholar
  11. 11.
    Hakomori S. Glycosphingolipids. Sci Am 1986;254:44–53.PubMedCrossRefGoogle Scholar
  12. 12.
    Itzkowitz SH, Kim YS. New carbohydrate tumor markers. Gastroenterology 1986;90:491–494.PubMedGoogle Scholar
  13. 13.
    Szulman AE. The histological distribution of the blood group substances in man as disclosed by immunofluorescence, III. The ABO and H antigens in embryos and fetuses from 18 mm in length. J Exp Med 1964;119:503–515.PubMedCrossRefGoogle Scholar
  14. 14.
    Szulman AE, Marcus DM. The histologic distribution of the blood group substances in man as disclosed by immunofluorescence. VI. The Lea and Leb antigens during fetal development. Lab Invest 1973;28:565–574.PubMedGoogle Scholar
  15. 15.
    Yuan M, Itzkowitz SH, Palekar A et al. Distribution of blood group antigens, A, B, H, Lea and Leb in normal, fetal and malignant colonic tissue. Cancer Res 1985;45:4499–4511.PubMedGoogle Scholar
  16. 16.
    Denk H, Tappeiner G, Holzmer HJ. Blood group substances (BGS) as oncofetal antigens in carcinoma of the distal colon. Eur J Cancer 1974;10:487–490.PubMedCrossRefGoogle Scholar
  17. 17.
    Cooper HS, Haesler WE. Blood group substances as tumor antigens in the distal colon. Am J Clin Pathol 1978;69:594–598.PubMedGoogle Scholar
  18. 18.
    Itzkowitz SH, Yuan M, Ferrell LD, Palekar A, Kim YS. Cancer-associated alterations of blood group antigen expression in human colorectal polyps. Cancer Res 1986;46:5976–5984.PubMedGoogle Scholar
  19. 19.
    Magnani JL, Nilsson B, Brockhaus M. A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-funcopentose. II. J Biol Chem 1982;257:14365–145369.PubMedGoogle Scholar
  20. 20.
    Magnani JL, Steplewski Z, Koprowski H, Ginsburg V. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19–9 in the sera of patients as a mucin. Cancer Res 1983;43:5489–5492.PubMedGoogle Scholar
  21. 21.
    Atkinson BF, Ernst CS, Herlyn M, Steplewski Z, Sears HF, Koprowski H. Gastrointestinal cancer-associated antigen in immunoperoxidase assay. Cancer Res 1982;42:4820–4823.PubMedGoogle Scholar
  22. 22.
    Raux H, Labbe F, Fondaneche M, Koprowski H, Burtin P. A study of gastrointestinal cancer-associated antigen (GICA) in human fetal organs. Int J Cancer 1983;32:315–319.PubMedCrossRefGoogle Scholar
  23. 23.
    Springer GF, Murthy SM, Desai PR, Fray WA, Tegtmeyer H, Scanion EF. Patients immune response to breast and lung carcinoma-associated Thomsen-Friedenreich (T) specificity. Klin Wochenschr 1982;60:121–131.PubMedCrossRefGoogle Scholar
  24. 24.
    Coon JS, Weinstein RS, Summers JL. Blood group precursor T-antigen expression in human urinary bladder carcinoma. Am J Clin Pathol 1982;77:692–699.PubMedGoogle Scholar
  25. 25.
    Boland CR, Montgomery CK, Kim, YS. Alterations in colonic mucin occurring with cellular differentiation and malignant transformation. Proc Natl Acad Sci USA 1982;79:2051–2055.PubMedCrossRefGoogle Scholar
  26. 26.
    Boland CR, Montgomery CK, Kim YS. A cancer associated mucin alteration in benign colonic polyps. Gastroenterology 1982;82:644–672.Google Scholar
  27. 27.
    Yuan M, Itzkowitz SH, Boland CR et al. Comparison of T-antigen expression in normal premalignant and malignant human colonic tissue using lectin and antibody immunohistochemistry. Cancer Res 1986;46:4841–4847.PubMedGoogle Scholar
  28. 28.
    Fukushima K, Hirota M, Terasaki PI et al. Characterization of sialysylated Lewis as a new tumor-associated antigen. Cancer Res 1984;44:5279–5285.PubMedGoogle Scholar
  29. 29.
    Brown A, Ellis IO, Embleton MJ, Baldwin RW, Turner DR, Hardcastle JD. Immunohisto-chemical localization of Y hapten and the structurally related H type-2 blood group antigen on large bowel tumors and normal adult tissues. Int J Cancer 1984;33:727–736.PubMedCrossRefGoogle Scholar
  30. 30.
    Hirota M, Fukushima K, Terasaki PI et al. Sialosylated Lewis in the sera of cancer patients detected by a cell-binding inhibition assay. Cancer Res 1985;45:1901–1905.PubMedGoogle Scholar
  31. 31.
    Sakamoto J, Furukawa K, Cordon-Cardo C et al. Expression of Lewisa, Lewisb, X and Y blood group antigens in human colonic tumors and normal tissue and in human tumor-derived cell lines. Cancer Res 1986;46:1553–1561.PubMedGoogle Scholar
  32. 32.
    Kannagi R, Fukushi Y, Tachikawa T et al. Quantitative and qualitative characterization of human cancer-associated serum glycoprotein antigens expressing fucosyl or sialyl-fucosyl type 2 chain polylactosamine. Cancer Res 1986;46:2619–2626.PubMedGoogle Scholar
  33. 33.
    Abe K, Hakomori S-I, Ohshiba S. Differential expression of difucosyl type 2 chain (Lev) defined by monoclonal antibody AH6 in different locations of colonic epithelia, various histological types of colonic polyps, and adenocarcinomas. Cancer Res 1986;46:2639–2644.PubMedGoogle Scholar
  34. 34.
    Itzkowitz SH, Yuan M, Fukushi Y et al. Lewisx and sialylated Lewisy-related antigen expression in human malignant and nonmalignant colonic tissues. Cancer Res 1986;46:2627–2632.PubMedGoogle Scholar
  35. 35.
    Kim YS, Yuan M, Itzkowitz SH et al. Expression of Lev and extended Lev blood group-related antigens in human malignant, premalignant, and non-malignant colonic tissues. Cancer Res 1986;46:5985–5992.PubMedGoogle Scholar
  36. 36.
    Yuan M, Itzkowitz SH, Ferrell LD et al. Expression of Lex and sialylated Lex antigens in human colorectal polyps. J Natl Cancer Inst 1987;78:479–488.PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1989

Authors and Affiliations

  • Young S. Kim
    • 1
  1. 1.Gastrointestinal Research Laboratory, Veterans Administration Medical Center, and Department of MedicineUniversity of California-San FranciscoSan FranciscoUSA

Personalised recommendations